시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 HER2 음성 유방암 시장 보고서(2025년)
HER2-Negative Breast Cancer Global Market Report 2025
상품코드 : 1720812
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,319,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,134,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,949,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

HER2 음성 유방암 시장 규모는 향후 몇 년 동안 높은 성장세를 보일 것으로 예상됩니다. 예측 기간의 성장은 알코올 소비 증가, 건강에 해로운 라이프스타일의 채택, 비만 유병률 증가, 흡연 증가, 효과적인 치료 솔루션에 대한 필요성 증가에 의해 주도될 것으로 예상됩니다. 주요 트렌드에는 진단 기술의 혁신, 표적 치료와 면역 치료의 통합, FDA 승인, 의료 기술의 발전 등이 포함됩니다.

유방암 발병률의 증가는 HER2 음성 유방암 시장의 성장을 견인할 것으로 예상됩니다. 유방암은 유방 조직에서 비정상적인 세포가 통제되지 않고 성장하는 것을 특징으로 하는 질환으로, 일반적으로 유관이나 소엽에서 시작됩니다. 유방암에 대한 인식이 높아지고 검진 기술이 발전하여 더 일찍, 더 자주 발견되는 등 여러 가지 요인이 유방암 발병률 증가에 영향을 미칩니다. HER2 음성 유방암 연구는 뚜렷한 종양 생물학을 이해하고 치료 결과를 개선하는 표적 치료법을 개발하는 데 매우 중요합니다. 예를 들어, 2024년 6월 미국 정부 기관인 질병통제예방센터는 2021년에 미국 여성 중 27만 2,454명의 여성이 유방암으로 진단되어 2022년에는 4만 2,211명이 사망했다고 보고했습니다. 이러한 유병률 증가는 효과적인 HER2 음성 유방암 치료제에 대한 수요가 증가하고 있음을 보여줍니다.

HER2 음성 유방암 시장을 선도하는 기업들은 새로운 치료법을 도입하고 제품군을 확장하며 시장 입지를 강화하기 위해 규제 승인을 적극적으로 추진하고 있습니다. 규제 승인은 정부 기관이 의약품과 치료법이 상용화 전에 안전성, 효능, 품질 기준을 충족하는지 확인하는 공식적인 허가를 의미합니다. 예를 들어, 2024년 10월 미국 생명공학 기업인 Genentech는 PIK3CA 변이가 있는 진행성 호르몬 수용체 양성(HR+), HER2 음성 유방암 표적 치료제로 Itovebi(이나볼리시브)에 대한 FDA 승인을 획득했습니다. 이번 승인으로 이토베비는 팔보시클립 및 풀베스트란트와 병용 투여할 수 있게 되어 표준 치료법에 비해 무진행 생존기간을 크게 향상시킬 수 있게 되었습니다. 새로 승인된 치료은 대안이 제한적인 환자들에게 중요한 치료 옵션을 제공하며, 치료의 혜택을 받을 가능성이 가장 높은 환자를 식별하는 데 있어 바이오마커 검사의 중요성을 강조합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

HER2-negative breast cancer is a type of breast cancer in which the cancer cells do not overexpress the HER2 protein, which is responsible for promoting tumor growth. This form of cancer generally grows more slowly than HER2-positive breast cancer and is treated using targeted therapies and chemotherapy.

The primary treatment options for HER2-negative breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of powerful drugs to destroy or inhibit the growth of cancer cells by targeting rapidly dividing cells in the body. Treatment is administered at various stages, including the early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The HER2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2-negative breast cancer market statistics, including HER2-negative breast cancer industry global market size, regional shares, competitors with HER2-negative breast cancer market share, detailed HER2-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the HER2-negative breast cancer industry. This HER2-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The HER2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.62 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period was driven by the rising incidence of breast cancer, increased awareness about the disease, higher healthcare spending, an aging population, and the expansion of healthcare infrastructure.

The HER2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.86 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period is expected to be driven by rising alcohol consumption, the adoption of unhealthy lifestyles, the increasing prevalence of obesity, higher tobacco use, and the growing need for effective treatment solutions. Key trends include innovations in diagnostic technologies, the integration of targeted therapies and immunotherapies, FDA approvals, and advancements in medical technology.

The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, typically originating in the ducts or lobules. Several factors contribute to the rising number of breast cancer cases, including heightened awareness and advancements in screening technologies, which lead to earlier and more frequent detection. HER2-negative breast cancer research is critical in understanding distinct tumor biology and developing targeted therapies that improve treatment outcomes. For example, in June 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2021, 272,454 new cases of breast cancer were diagnosed among females in the United States, with 42,211 deaths recorded in 2022. This growing prevalence underscores the increasing demand for effective HER2-negative breast cancer treatments.

Leading companies in the HER2-negative breast cancer market are actively pursuing regulatory approvals to introduce new treatments, expand their product offerings, and strengthen their market presence. Regulatory approvals represent official authorizations granted by government agencies, ensuring that drugs and treatments meet safety, efficacy, and quality standards before commercialization. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval enables Itovebi to be administered in combination with palbociclib and fulvestrant, significantly enhancing progression-free survival compared to standard treatments. The newly approved regimen offers a crucial treatment option for patients with limited alternatives, highlighting the importance of biomarker testing in identifying those most likely to benefit from the therapy.

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, partnered with Pfizer Inc. to evaluate the combination of atirimociclib, Pfizer's investigational selective CDK4 inhibitor, with RLY-2608 and fulvestrant in patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. This collaboration seeks to leverage the distinct properties of both drugs to minimize off-target toxicity, which has historically limited the effectiveness of non-selective agents. Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, continues to play a key role in the development of innovative treatments for HER2-negative breast cancer.

Major players in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2-Negative Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2-negative breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for her2-negative breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2-negative breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. HER2-Negative Breast Cancer Market Characteristics

3. HER2-Negative Breast Cancer Market Trends And Strategies

4. HER2-Negative Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2-Negative Breast Cancer Growth Analysis And Strategic Analysis Framework

6. HER2-Negative Breast Cancer Market Segmentation

7. HER2-Negative Breast Cancer Market Regional And Country Analysis

8. Asia-Pacific HER2-Negative Breast Cancer Market

9. China HER2-Negative Breast Cancer Market

10. India HER2-Negative Breast Cancer Market

11. Japan HER2-Negative Breast Cancer Market

12. Australia HER2-Negative Breast Cancer Market

13. Indonesia HER2-Negative Breast Cancer Market

14. South Korea HER2-Negative Breast Cancer Market

15. Western Europe HER2-Negative Breast Cancer Market

16. UK HER2-Negative Breast Cancer Market

17. Germany HER2-Negative Breast Cancer Market

18. France HER2-Negative Breast Cancer Market

19. Italy HER2-Negative Breast Cancer Market

20. Spain HER2-Negative Breast Cancer Market

21. Eastern Europe HER2-Negative Breast Cancer Market

22. Russia HER2-Negative Breast Cancer Market

23. North America HER2-Negative Breast Cancer Market

24. USA HER2-Negative Breast Cancer Market

25. Canada HER2-Negative Breast Cancer Market

26. South America HER2-Negative Breast Cancer Market

27. Brazil HER2-Negative Breast Cancer Market

28. Middle East HER2-Negative Breast Cancer Market

29. Africa HER2-Negative Breast Cancer Market

30. HER2-Negative Breast Cancer Market Competitive Landscape And Company Profiles

31. HER2-Negative Breast Cancer Market Other Major And Innovative Companies

32. Global HER2-Negative Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Negative Breast Cancer Market

34. Recent Developments In The HER2-Negative Breast Cancer Market

35. HER2-Negative Breast Cancer Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기